Biogen (BIIB) PT Raised to $408 at Cowen
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil pares losses as market weighs Saudi supply concerns, Middle East tensions
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Biogen (BIIB) PT Raised to $400 at Oppenheimer
January 26, 2018 6:46 AM ESTOppenheimer raised its price target on Biogen (NASDAQ: BIIB) to $400.00 (from $380.00) while maintaining a Outperform rating.
Analyst Jay Olson commented, "BIIB shares outperformed yesterday (+2.1% vs. NBI +0.7% and S&P 500 +0.1%) on strong 4Q17 financial results and confidence expressed by management regarding execution on key... More
Biogen (BIIB) PT Raised to $403 at BMO Capital on 4Q Report; '2018 Guidance Above Street With Room to Grow'
January 25, 2018 3:48 PM ESTBMO Capital raised its price target on Biogen (NASDAQ: BIIB) to $403.00 (from $394.00) while maintaining a Outperform rating, following the company's fourth quarter earnings report.
Analyst M. Ian Somaiya notes a positive outlook on the shares, as the company reported fourth quarter revenues above... More
Biogen (BIIB) Misses Q4 EPS by 19c, Revenue Beats; Offers Outlook
January 25, 2018 6:31 AM EST(Updated - January 25, 2018 6:33 AM EST)
Biogen (NASDAQ: BIIB) reported Q4 EPS of $5.26, $0.19 worse than the analyst estimate of $5.45. Revenue for the quarter came in at $3.31 billion versus the consensus estimate of $3.08 billion.
GUIDANCE:
Biogen sees FY2018 EPS of $24.20-$25.20... More
